Daily Newsletter

16 October 2023

Daily Newsletter

16 October 2023

ACE and KGH explore bed allocation improvement via AI

The PoC aims to assist staff and ensure patients are in the right beds at the right times.

October 13 2023

The Accelerated Capability Environment (ACE) has collaborated with Kettering General Hospital (KGH) to develop a proof of concept (PoC) using artificial intelligence (AI) to improve patient bed allocation decisions in hospitals.

The PoC aims to ensure patients are in the right beds at the right times, and assist staff in making the best bed allocation choices.

The virtual hospital environment PoC is modelled on key KGH wards and was created with the help of ACE's Vivace supplier community and the NHS England AI Lab.

It uses historic admission data to predict demand and generate bed suggestions for patients from the emergency department, and explains its recommendations to build trust in the AI tool.

The AI tool maintains human involvement through an explainability or human-in-the-loop approach, allowing schedulers to make the final bed allocation decisions.

This PoC claims to offer benefits such as more efficient bed scheduling using machine learning optimisation, improved decision-making with better data, reduced bed moves, and improved patient outcomes with cost reductions.

Future steps include supporting multiple admissions, transfers, and discharges, integrating with existing hospital systems, and expanding to cover all specialities, wards, and bed types.

ACE recently collaborated with the NHS's AI Skunkworks to develop an AI tool for faster Parkinson's Disease diagnosis, expediting research by months, or even years.

The tool automatically identifies areas of interest in digitised brain images, reducing diagnosis time, and recorded a 92% accuracy rate.

It is claimed to have the potential for real-world applications and future use in differentiating disease stages and identifying dementia indicators in brain scans of live patients.

AI will become a key driver of medical device innovation

With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close